Business Wire

WELLO2

18.5.2020 07:02:06 CEST | Business Wire | Press release

Share
WellO2: Counter Pressure Steam Breathing Helps With Voice Symptoms

Training with a counter pressure steam breathing device has the potential to improve voice quality, as revealed in a recent pilot study in Finland. A report on the study was published in Journal of Voice, a peer-reviewed publication regarded as the world's premiere journal for voice medicine and research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005004/en/

The protocol of another study, now investigating benefits of using WellO2, a unique counter pressure steam breathing device, with patients with chronic obstructive pulmonary symptoms, has been approved by the ethical committee of the University of Tampere. Both studies focus on the effects of the combination of the inspiratory and expiratory muscle training with warm steam.

Voice professionals have found help

Even before the Finnish study came out, various renown voice professionals have been using WellO2 to help with their voice problems. Among the artists is Uriah Heep’s lead singer Bernie Shaw , who has warmly endorsed WellO2 (see link, below).

The aim of the Finnish pilot study was to determine the efficacy of the 4-week breathing exercise intervention on participants with voice symptoms. Six non-smoking women, mean age 49, experiencing voice symptoms made respiratory muscle exercises for a month with counter pressure on both inspiration and expiration and with warm steam. Speech samples were acoustically measured and perceptually analyzed using the GRBAS, the grade, roughness, breathiness, asthenia and strain scale. Afterwards, perceived voice symptoms and self-reported effort in breathing and phonation were analyzed.

Participants: Breathing was significantly less effortful

The total score of the Acoustic Voice Quality Index (AVQI) and some of its subcomponents, namely shimmer and harmonic-to-noise ratio, and the perceptually evaluated grade, roughness, and strain indicated significantly improved voice quality. However, neither the nature or frequency of the experienced voice symptoms nor the perceived phonatory effort changed as the function of intervention. According to the participants, their breathing was significantly less effortful after the intervention, although no significant changes were observed in the objective respiratory measurements with a spirometer.

According to the study, training with the WellO2 device has the potential to improve voice quality. However, the effects of using WellO2 need to be confirmed by further studies with a larger number of participants, the pilot study concluded.

New studies with WellO2 and chronic obstructive pulmonary symptoms

The ethical committee of the University of Tampere recently gave a positive statement for the clinical study of WellO2 with patients with chronic obstructive pulmonary symptoms. The team is testing the effect of WellO2 device for the respiratory muscle exercises that provides counter pressure. There are several hundreds of referred studies on steam inhalation and counter pressure breathing. None have found any severe side effects for using such devices.

Patented WellO2 counter pressure steam breathing device was developed by Hapella Oy, Finland. The device has been available since 2016 as a non-medical device. Over 35 000 devices have been sold in Finland, alone. It is sold both in pharmacies and other stores, like electric commodity store chain of Elgiganten in Sweden and Elkjøp in Norway. Wello2 is available on e-commerce, also at various Amazon e-stores, e.g. in Italy and Germany.

Medical references & links:
https://wello2.com/blogs/news/wello2-counter-pressure-steam-breathing-helps-with-voice-symptoms

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vena Completes Acterys Acquisition to Accelerate Orchestrated Planning for the Microsoft Ecosystem26.3.2026 14:00:00 CET | Press release

The combination connects AI-driven financial and operational planning, analytics and execution across Microsoft Excel and Power BI, removing decision latency for Microsoft-centric enterprises. Vena, the AI-powered Orchestrated Performance Management platform purpose-built to fully amplify the Microsoft technology ecosystem, today announced it has completed its acquisition of Acterys, the leading Microsoft Power BI–based operational planning and app development platform. The move strengthens Vena’s Orchestrated Planning solution and begins phased integration of the two platforms. Modern enterprises are struggling to keep up with the volatility and dynamism of the markets they serve. Market drivers and signals shift rapidly, and the ability to assess, plan and execute with confidence and speed is more important than ever. These forces, combined with overwhelming data density and disparity, have created a new constraint: decision latency—the time between signal and action. As that gap wid

Nearly Half of Global C-Suites Plan U.S. Expansion Within 12 Months, as Supply Chain and Capital Access Drive Growth26.3.2026 14:00:00 CET | Press release

• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years • 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion • 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape. CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expa

Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release

The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release

COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye